

Cancer Disparities Research Partnership (CDRP) Program Process & Outcome Evaluation

Paul Young, MBA, MPH
Amanda Greene, PhD, MPH, RN
NOVA Research Company

Rosemary Wong, PhD
NCI/RRP Evaluation Project Officer



APHA, November 5, 2007

Overview

- CDRP Program Background
- Evaluation Paradigm & Process
- Evaluation Questions and Their Measurement
- Preliminary Findings


Purpose of CDRP Program

Build and stabilize research capacity in radiation oncology in community-based institutions that care for a disproportionate number of medically underserved, low-income, racial and ethnic minorities and other populations experiencing cancer health disparities.

CDRP Characteristics


- 5-year U56 cooperative grant
- Began in 2002 with 2 sites, total of 6 sites by FY 2003
- Pilot program for community institutions new to NCI clinical research
- Target populations are those experiencing cancer health disparities
- Focus on patients who require radiation therapy cancer treatment

CDRP Five-Component Model




Innovative Funding Mechanism

Traditional



CDRP



CDRP: What Community & NCI Gain

- Patients have access to state-of-the-art cancer care – Phase II, III and investigator-initiated trials
 - Community hospitals offer NCI approved clinical trials
 - Hospitals build research programs around the grant, invest in additional personnel
 - Multidisciplinary care and successful collaborative partnerships attained

Building/Stabilizing Clinical Trials Research In Community Institutions

Grantees	Service Area Population	Target Population
Rapid City Regional Hospital, Rapid City, SD	300,000	Native American
Laredo Medical Center, Laredo, TX	177,000	Hispanic/Latino
Centinela Freeman Regional Medical Center, Inglewood, CA	100,000	Hispanic/Latino African American
New Hanover Regional Medical Center, Wilmington, NC	616,000	African American Poor Underserved
Singing River Hospital, Pascagoula, MS	200,000	African American
UPMC McKeesport Hospital, McKeesport, PA	935,000	African American Poor Underserved


Purpose of Evaluation

- Measure relevance, effectiveness, and impact of CDRP Program in a consistent fashion
- Prepare evaluation findings to identify Program attributes to be applied to new settings
- Provide meaningful reports to stakeholders within and outside the National Cancer Institute

CDRP Program Evaluation

- 2005 - Evaluation feasibility study
- 2006-2009 – Process and outcome evaluation


Program Evaluation Steps



Evaluation Planning

- Identify CDRP goals and expected outcomes
- Develop Conceptual Framework and Logic Model collaboratively with NCI
- Develop and implement Evaluation Plan/Design (Mixed Methods)
- Input from CDRP Evaluation Advisory and Experts Committees

CDRP Program Conceptual Framework



Key Evaluation Questions

- Achievement of radiation oncology **clinical research in community-based health care institutions** serving populations experiencing health disparities
- Increase in **clinical trial participation** among target populations
- Impact of **partnerships** between awardee institutions and academic research center mentors
- Impact/Use of **TELESYNERGY®**
- Influence of **patient navigation** and **community outreach**

Data Sources and Metrics

- Determine data needs
- Review existing data, determine new data/measures needed
- Data sources:
 - Data abstraction from grantee annual progress reports
 - Selected periodic data queries of CDRP grantees
 - PI/Co-PI and academic partner in-depth interviews
 - Comparison hospitals survey
 - Evaluation site visits

Quantitative Quarterly Data Report

- Infrastructure: new researchers trained
- Number patients screened for clinical trials
- Open clinical trials and accruals
- Social science and health services studies
- Partnership activities
- TELESYNERGY® use
- Patient navigation data
- Outreach activities

New Researchers

Type of Researcher	Before CDRP	After CDRP
Investigator (MD or PhD)	3	11
Research Coordinator	3	12
Research Nurse	4	11
Data Manager	1	6
Patient Navigator	0	34
Grants Administrator	0	6
Other Researchers	<u>0</u>	<u>17</u>
Total	11	97

Clinical Research

Types of Clinical Research	Before CDRP	After CDRP
	N	N
Investigator-Initiated Studies	0	18
RTOG Trials	3	53
Other Cooperative Group Trials	30	86
Behavioral Studies & Prevention Trials	1	17
Pharmaceutical & Industry Trials	8	22
Other Types of Studies	<u>10</u>	<u>19</u>
Total	52	215

Total Number of Patients Accrued or Navigated by Race/Ethnicity for All CDRP Sites

Race/Ethnicity	Total # Accrued to Clinical Trials	Total # Navigated
American Indian/Alaska Native	47	215
Asian	2	16
Non-Hispanic Black or African American	46	468
Non-Hispanic White	372	435
Hispanic/Latino	323**	390**
More than 1 race, Unknown	0	4
Total	790	1,726

* Start of CDRP to June 2007; does not include social science studies accrual

** Includes STAR & SABOR trials

Report of Findings

- Yearly increase of disparity population patient accrual into cancer clinical trials
- Increased participation of new researchers
- Yearly patient accrual to variety of clinical research activities
- Presentations at local, regional and national meetings
- Publications on various aspects of CDRP programs
- Initiation of annual NCI/ASTRO Cancer Disparity Symposium
- Demonstrate community education/outreach and patient navigation are critical key components for patient recruitment in successful CDRP program

Lessons Learned

- Need target-population appropriate research
- Need minimum of 2 or more radiation oncologists or surgical/medical oncologist
- Additional time for infrastructure development, more formal orientation
- Additional intrinsic and extrinsic incentives for mentor/partners
- Community outreach needed prior to clinical research recruitment

Acknowledgements

- NOVA acknowledges the substantive collaboration and input of NCI/RRP staff
 - Norman Coleman, MD,
Associate Director, DCTD
 - Vikram Bhadrasain, MD,
Chief, Clinical Radiation Oncology Branch
 - Jean Lynn, RN, MPH, OCN®
Director of Outreach, Cancer Expert Corps
- Evaluation performed under
NCI Contract No. 263-FQ-609460